Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Alogliptin Benzoate,Pioglitazone
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Teijin Pharma
Deal Size : $1,250.0 million
Deal Type : Divestment
Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma Limited
Details : The portfolio divested to Teijin Pharma was comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.
Brand Name : Liovel
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 01, 2021
Lead Product(s) : Alogliptin Benzoate,Pioglitazone
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Teijin Pharma
Deal Size : $1,250.0 million
Deal Type : Divestment
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Teijin Pharma
Deal Size : $1,250.0 million
Deal Type : Divestment
Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited
Details : The portfolio to be divested to Teijin Pharma is comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.
Brand Name : Nesina
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 26, 2021
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Teijin Pharma
Deal Size : $1,250.0 million
Deal Type : Divestment
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Celltrion
Deal Size : $278.0 million
Deal Type : Divestment
Takeda to Divest Select APAC Assets to Celltrion for $278M
Details : The portfolio to be divested to Celltrion includes a variety of OTC products and pharmaceutical products such as Nesina® and Edarbi® and Products in a variety of indications.
Brand Name : Nesina
Molecule Type : Small molecule
Upfront Cash : $266.0 million
June 11, 2020
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Celltrion
Deal Size : $278.0 million
Deal Type : Divestment
LOOKING FOR A SUPPLIER?